An epigenetic switch regulates the ontogeny of AXL-positive/EGFR-TKi-resistant cells by modulating miR-335 expression
Despite current advancements in research and therapeutics, lung cancer remains the leading cause of cancer-related mortality worldwide. This is mainly due to the resistance that patients develop against chemotherapeutic agents over the course of treatment. In the context of non-small cell lung cance...
Main Authors: | Polona Safaric Tepes, Debjani Pal, Trine Lindsted, Ingrid Ibarra, Amaia Lujambio, Vilma Jimenez Sabinina, Serif Senturk, Madison Miller, Navya Korimerla, Jiahao Huang, Lawrence Glassman, Paul Lee, David Zeltsman, Kevin Hyman, Michael Esposito, Gregory J Hannon, Raffaella Sordella |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2021-07-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/66109 |
Similar Items
-
Decreased epidermal AXL expression and increased infiltration of AXL‐expressing dendritic cells in psoriasis
by: Yukiko Ito, et al.
Published: (2023-12-01) -
How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?
by: Chuanhao TANG, et al.
Published: (2013-07-01) -
The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
by: Yun Beom Sang, et al.
Published: (2022-03-01) -
Mechanism of action of adapalene for treating EGFR‐TKI‐induced skin disorder
by: Chihiro Mimura, et al.
Published: (2024-03-01) -
Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway
by: Qi Sun, et al.
Published: (2022-06-01)